Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trialLajos Pusztai, Jong-Hyeon Jeong, Yun Gong, et al.
ESMO Open|September 27, 2019
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)Ines Vaz-Luis, Paul Cottu, Christel Mesleard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancersCharles Coutant, Roman Rouzier, Yuan Qi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2025
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trialFrédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerKathy D Miller, Véronique Diéras, Nadia Harbeck, et al.
Cancer Letters|November 11, 2025
Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistanceGrigory A Puzanov, Clémence Astier, Dimitris Papakonstantinou, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2021
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre studyGiuseppe Curigliano, Miguel Martin, Komal Jhaveri, et al.
Breast (Edinburgh, Scotland)|September 25, 2012
Gene copy number variations in breast cancer of Sub-Saharan African womenMadani Ly, Alexander Valent, Gangaly Diallo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization arrayFabrice Andre, Bastien Job, Philippe Dessen, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trialLajos Pusztai, Jong-Hyeon Jeong, Yun Gong, et al.
ESMO Open|September 27, 2019
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO)Ines Vaz-Luis, Paul Cottu, Christel Mesleard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancersCharles Coutant, Roman Rouzier, Yuan Qi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 18, 2025
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trialFrédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerKathy D Miller, Véronique Diéras, Nadia Harbeck, et al.
Cancer Letters|November 11, 2025
Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistanceGrigory A Puzanov, Clémence Astier, Dimitris Papakonstantinou, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2021
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre studyGiuseppe Curigliano, Miguel Martin, Komal Jhaveri, et al.
Breast (Edinburgh, Scotland)|September 25, 2012
Gene copy number variations in breast cancer of Sub-Saharan African womenMadani Ly, Alexander Valent, Gangaly Diallo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization arrayFabrice Andre, Bastien Job, Philippe Dessen, et al.
Lancet (London, England)|July 31, 2002
Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.
Pageof 15